General Clinical Chemistry Analyzers and Accessories
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 10MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 10MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 1MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 1MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TC 14012, Peptidomimetic C x CR4 antagonist, 5MG
MW 2066.4 Da, Purity >95%. TC 14012, Peptidomimetic CXCR4 antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam EHop-016, Rac GTPase inhibitor, 5MG
MW 430.5 Da, Purity >98%. Specific Rac GTPase inhibitor. Analog of NSC-23766 (ab142161). Approximately 100-fold more potent against Rac (IC₅₀ = 1.1 μM) than NSC-23766. Specific for Rac1 and Rac3 at concentrations of ≤5 μM. At higher concentrations (10μM) inhibits the the related Rho GTPase Cdc42. Also inhibits the activity of the Rac downstream effector p21-activated kinase (PAK), lamellipodia extension, and cell migration in metastatic cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ticagrelor, P2Y12 receptor antagonist, 10MG
MW 522.6 Da, Purity >98%. Reversible antagonist of the platelet purinergic P2Y12 receptor, the main receptor responsible for ADP-induced platelet aggregation. Changes the conformation of the P2Y12 receptor, resulting in reversible, concentration dependent inhibition of the receptor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 5MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Daclatasvir (BMS-790052), HCV NS5A protein inhibitor, 10MG
MW 738.9 Da, Purity =97%. Daclatasvir a potent, direct acting, small molecule inhbitor of HCV NS5A protein. It inhbibits replicons expressing a wide range of HCV genotypes with EC₅₀ values in the pM range (9 and 71 pM against the 1b and 2a genotypes, respectively). It also inhibits infection by the JFH-1 genotype 2a virus in cultured cells. Daclatasvir is thought to inhibit relication of the HCV viral genome by affecting the subcellular localization of HCV NS5A and preventing its incorporation into relication complexes. In HCV-infected Huh7 cells, Daclatasvir (1 nM) inhibits viral RNA synthesis and viron assembly. Daclatasvir displays moderate activity against the OAT1B1 (IC₅₀ = 1.5 μM) and OAT1B3 (IC₅₀ = 3.27 μM) organic anion transporters.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ticagrelor, P2Y12 receptor antagonist, 25MG
MW 522.6 Da, Purity >98%. Reversible antagonist of the platelet purinergic P2Y12 receptor, the main receptor responsible for ADP-induced platelet aggregation. Changes the conformation of the P2Y12 receptor, resulting in reversible, concentration dependent inhibition of the receptor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RITA, p53 activator, 25MG
MW 292.4 Da, Purity >98%. p53 activator. Tricyclic thiophene derivative that binds to p53 and induces its accumulation in tumor cells. Prevents p53-HDM2 (MDM2) interaction in vitro and in vivo and affects p53 interaction with several negative regulators. Induces expression of p53 target genes and apoptosis in various tumor cell lines expressing wild-type p53.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IO x 2, HIF-1alpha prolyl hydro x ylase-2 (PHD2) inhibitor, 5MG
MW 352.3 Da, Purity >98%. Potent, cell-permeable, selective HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor (IC₅₀ = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CK869, Actin-related protein 2/3 (Arp2/3) comple x inhibitor, 10MG
MW 394.3 Da, Purity >98%. Inhibitor of human and bovine actin-related protein 2/3 (Arp2/3) complex. Inhibits actin polymerization with bovine Arp2/3 complex (IC₅₀ = 11 μM) and inhibits the formation of actin filament comet tails by Listeriamonocytogenes in infected SKOV3 cells (IC₅₀ = 7 μM) . Does not inhibit budding or fission yeast Arp2/3 complexes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RITA, p53 activator, 5MG
MW 292.4 Da, Purity >98%. p53 activator. Tricyclic thiophene derivative that binds to p53 and induces its accumulation in tumor cells. Prevents p53-HDM2 (MDM2) interaction in vitro and in vivo and affects p53 interaction with several negative regulators. Induces expression of p53 target genes and apoptosis in various tumor cell lines expressing wild-type p53.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IO x 2, HIF-1alpha prolyl hydro x ylase-2 (PHD2) inhibitor, 25MG
MW 352.3 Da, Purity >98%. Potent, cell-permeable, selective HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor (IC₅₀ = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3.
The product is subject to the following: Abcam Restricted Use Statement